Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Will This Stock Rule the Next Generation of Cholesterol Medicine?

By Dan Carroll - Mar 24, 2014 at 6:30PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Amgen's fired on all cylinders in 2014 as up-and-coming PCSK9 inhibitor evolocumab has hit its targets in trial after trial. Can it beat stiff competition to become this big biotech's next blockbuster?

Big biotech stock Amgen's ( AMGN 1.21% ) in no short supply of optimism for eager investors. Despite the company's so-so earnings projections going forward, it's thrived behind star drugs Enbrel and Neulasta, which have shown no signs of slowing down their blockbuster pace. That financial strength has propelled Amgen's stock to a gain of more than 34% over the past year, but the company's sturdy pipeline could be ready to deliver another dose of good news.

Amgen's developmental PCSK9 inhibitor evolocumab struck gold in a recent clinical trial, and this up-and-coming cholesterol-fighting drug's fueling high hopes of a new blockbuster to add to Amgen's drug portfolio. The cholesterol medication niche isn't a small one, however, and rival drugs from Regeneron ( REGN 1.61% ) and Pfizer ( PFE 0.47% ), among others, are racing against Amgen to capture the PCSK9 crown -- and the huge opportunity that comes with it -- in the near future.

Can Amgen's evolocumab make it to the market and become investors' next big hope for this star-studded big biotech? Find out what you need to know in the video below, as Motley Fool contributor Dan Carroll takes you through this promising health-care niche -- and why Amgen and its investors are poised to score big if evolocumab can win over regulators.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Amgen Inc. Stock Quote
Amgen Inc.
AMGN
$211.32 (1.21%) $2.53
Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$51.72 (0.47%) $0.24
Sanofi Stock Quote
Sanofi
SNY
$47.91 (0.74%) $0.35
Regeneron Pharmaceuticals, Inc. Stock Quote
Regeneron Pharmaceuticals, Inc.
REGN
$635.09 (1.61%) $10.09

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
633%
 
S&P 500 Returns
140%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/07/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.